OncXerna Therapeutics Announces Final Results and New Xerna™ TME Panel Biomarker Data from a Phase 2 Trial of Bavituximab Plus Pembrolizumab in Patients with Previously Untreated Advanced Hepatocellular Carcinoma - read this article along with other careers information, tips and advice on BioSpace
/CNW/ Carcell Biopharma ("Carcell"), an EVX Ventures company, is pleased to announce Prof. Harvey Lodish as the Chair of the Scientific Advisory Board. He.
/PRNewswire/ Carcell Biopharma ("Carcell"), an EVX Ventures company, is pleased to announce Prof. Harvey Lodish as the Chair of the Scientific Advisory.
SINGAPORE and SHANGHAI, Dec. 19, 2022 /PRNewswire/ Carcell Biopharma ("Carcell"), an EVX Ventures company, is pleased to announce Prof. Harvey Lodish as the Chair of the Scientific Advisory Board. He joins Prof. Jianzhu Chen of the Massachusetts Institute of Technology (MIT) and Dr. Hagop Youssoufian of Brown University on Carcell's Scientific Advisory Board to propel scientific advancement of its cell and gene therapy platforms. Prof. Lodish brings onboard decades of experience in biotech and especially red blood cell (RBC)-based therapeutics to the team. He is a founding member of the Whitehead Institute for Biomedical Research and a Professor of Biology and of Biological Engineering at MIT. During his illustrious scientific career, he uncovered many groundbreaking discoveries in molecular and cell biology and has trained brilliant individuals who have gone on to win Nobel Prizes: Aaron Ciechanover (Chemistry, 2004) and James Rothman (Physiology or Medicine, 2013). Ei